Holen Sie sich die Stockscreener-App
385.74
1.01%
3.865
Handel nachbörslich:
385.74
0.005
+0.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$381.87
Offen:
$381.91
24-Stunden-Volumen:
1.84M
Relative Volume:
1.06
Marktkapitalisierung:
$98.90B
Einnahmen:
$11.39B
Nettoeinkommen (Verlust:
$3.64B
KGV:
27.57
EPS:
13.99
Netto-Cashflow:
$3.50B
1W Leistung:
+0.68%
1M Leistung:
-0.37%
6M Leistung:
-22.90%
1J Leistung:
-16.71%
1-Tages-Spanne:
$379.72
$387.48
1-Wochen-Bereich:
$374.17
$387.48
52-Wochen-Spanne:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
What Vertex Pharmaceuticals (VRTX)'s FDA Breakthrough for Povetacicept Means for Kidney Disease Pipeline - Yahoo Finance
Perigon Wealth Management LLC Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
State of Alaska Department of Revenue Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True? - Nasdaq
Leerink Partnrs Issues Pessimistic Outlook for VRTX Earnings - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded by Leerink Partnrs to Strong-Buy Rating - MarketBeat
TD Private Client Wealth LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Banque Pictet & Cie SA - MarketBeat
Trump’s 100% Drug Tariff Bombshell: Which Pharma Stocks Would Soar or Crash? - Investing.com
Key advancements across Vertex’ kidney portfolio - The Pharma Letter
Vertex Pharmaceuticals’ Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating - TipRanks
Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership - Seeking Alpha
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial - TipRanks
Leerink Partners Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Vertex Announces Key Advancements Across Kidney Portfolio - Yahoo Finance
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Vertex stock rating upgraded to Outperform by Leerink Partners on pain drug outlook - Investing.com
MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Leerink Partners Upgrades Vertex Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $456 From $458 - MarketScreener
Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth - TipRanks
Beacon Investment Advisory Services Inc. Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
4,352 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Harrell Investment Partners LLC - MarketBeat
Biotech Stocks To Follow TodaySeptember 21st - MarketBeat
Norden Group LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns - Seeking Alpha
Vertex secures all-star assist for Journavx, signing up NBA's Jayson Tatum for pain drug promotion - Fierce Pharma
Foster Victor Wealth Advisors LLC Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Public Employees Retirement System of Ohio Has $47.22 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating - TipRanks
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by CCM Investment Advisers LLC - MarketBeat
Promising Biotech Stocks To ConsiderSeptember 20th - MarketBeat
Sovran Advisors LLC Has $646,000 Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Sells 25,740 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assenagon Asset Management S.A. Purchases 34,614 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Avanza Fonder AB Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
IFM Investors Pty Ltd Purchases 1,781 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Kingstone Capital Partners Texas LLC Invests $23.87 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Atle Fund Management AB Purchases 1,520 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX - Business Wire
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Wedmont Private Capital - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Baader Bank Aktiengesellschaft - MarketBeat
Andrew Hill Investment Advisors Inc. Purchases 1,430 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Channel Wealth LLC Acquires 11,833 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
UMB Bank n.a. Sells 1,094 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.51%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):